UBS lowered the firm’s price target on Nurix Therapeutics (NRIX) to $26 from $30 and keeps a Buy rating on the shares. The firm sees asymmetric upside at the current stock price with multiple data catalysts in the next 12 months, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX: